David Loew will leave his position as the head of Sanofi’s vaccine division to become the Chief Executive Officer of Ipsen.
Loew will begin his new role on 1 July and will be tasked with ensuring the company continues to advance products in its pipeline. He replaces former CEO David Meek who left the company in December to join FerGene. Loew’s appointment comes as the company is trying to offset potential losses from a generic threat to its cancer treatment, Somatuline. The company is also attempting to push forward with its bone disorders product palovarotene, despite some clinical setbacks.
Loew said in a brief statement that he was deeply honoured to take over as the CEO of Ipsen and is excited to take over the company, and plans to focus on company’s mission of delivering innovative solutions to patients with high unmet medical needs.
David Loew had previously helmed Sanofi Pasteur Vaccines since 2016, where he oversaw licensing deals and acquisitions. Before this role, Loew served as the head of commercial operations in Europe where he was responsible for prescription, consumer healthcare and generics businesses across the EU region